Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Aug;30(8):1657-64.
doi: 10.1161/ATVBAHA.110.207977. Epub 2010 May 20.

Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels

Affiliations

Cholesteryl ester transfer protein polymorphism (TaqIB) associates with risk in postinfarction patients with high C-reactive protein and high-density lipoprotein cholesterol levels

James P Corsetti et al. Arterioscler Thromb Vasc Biol. 2010 Aug.

Abstract

Objective: To investigate the roles of inflammation and a cholesteryl ester transfer protein (CETP) polymorphism potentially related to recent findings demonstrating coronary risk with increasing high-density lipoprotein cholesterol (HDL-C) level.

Methods and results: A novel graphical exploratory data analysis tool allowed the examination of coronary risk in postinfarction patients relating to HDL-C and C-reactive protein levels. Results demonstrated a high-risk subgroup, defined by high HDL-C and C-reactive protein levels, exhibiting larger HDL particles and lower lipoprotein-associated phospholipaseA(2) levels than lower-risk patients. Subgroup CETP-associated risk was probed using a functional CETP polymorphism (TaqIB, rs708272). In the high-risk subgroup, multivariable modeling revealed greater risk for B2 allele carriers (less CETP activity) versus B1 homozygotes (hazard ratio, 2.41; 95% CI, 1.04 to 5.60; P=0.04). Within the high-risk subgroup, B2 allele carriers had higher serum amyloid A levels than B1 homozygotes. Evidence also demonstrates that CETP genotypic differences in HDL subfraction distributions regarding non-HDL-C and lipoprotein-associated phospholipaseA(2) may potentially relate to impaired HDL remodeling.

Conclusions: Postinfarction patients with high HDL-C and C-reactive protein levels demonstrate increased risk for recurrent events. Future studies should aim at characterizing altered HDL particles from such patients and at elucidating the mechanistic details related to inflammation and HDL particle remodeling. Such patients should be considered in drug trials involving an increase in HDL-C level.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Outcome event mapping of estimated coronary event rate over the risk domain of HDL-C and CRP ranks for the study population. Full-scale outcome rate along z-axis is 0.40. The red iso-contour at peak base corresponds to mean event rate for the total population (0.159). For reference, HDL ranks 480, 660, and 730 correspond approximately to: HDL-C of 1.04 mmol/l (40mg/dL), 1.30 mmol/l (50 mg/dL), and 1.55 mmol/l (60 mg/dL), respectively; while CRP ranks 195 and 465 correspond to CRP of 1 mg/L and 3 mg/L, respectively.
Figure 2
Figure 2
Outcome event mappings of estimated coronary event rates over the risk domain of HDL-C and CRP ranks as a function of the dichotomized TaqIB polymorphism of CETP for: A. B1 homozygotes and B. B2 allele carriers. Full-scale outcome rate along z-axis is 0.50. See Figure 1 legend for correspondence of HDL-C and CRP ranks with levels.

Comment in

References

    1. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target - a systematic review. JAMA. 2007;298:786–798. - PubMed
    1. Joy T, Hegele RA. Is raising HDL a futile strategy for atheroprotection? Nat Rev Drug Discovery. 2008;7:143–155. - PubMed
    1. Corsetti JP, Zareba W, Moss AJ, Rainwater DL, Sparks CE. Elevated HDL is a risk factor for recurrent coronary events in a subgroup of non-diabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis. 2006;187:191–197. - PubMed
    1. deGoma EM, Leeper NJ, Heidenreich PA. Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol. J Am Coll Cardiol. 2008;51:49–55. - PubMed
    1. van der Steeg WA, Holme I, Boekholdt SM, Larsen ML, Lindahl C, Stroes ESG, Tikkanen MJ, Wareham NJ, Faergeman O, Olsson AG, Pedersen TR, Khaw KT, Kastelein JJP. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk. J Am Coll Cardiol. 2008;51:634–642. - PubMed

Publication types

MeSH terms